Caribou Biosciences to Evaluate Strategic Alternatives
Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced it will evaluate strategic alternatives, including potential mergers or acquisitions, to maximize stockholder value. The company plans to discontinue further development of its allogeneic CAR-T cell therapy programs vispa-cel and CB-011 due to financing…